Table II.

Summary table to show experimental design variation and protection from clinical disease in pigs following vaccination with FMD vaccines formulated for emergency use.

Breed	Vaccine	Challenge	Days vaccinated before exposure															Ref.
			0	2	3	4	5	6	7	8	9	10	12	14	16	21	29
?a	A119b 10 μg/dosed Oile	Homologous direct contact with 2 infected pigs (for 10 days?)	0/5		3/4c		2/4		4/4			3/4		14/14				[38]
Large white	C1 Noville X2 cattle dose Aqueous	Homologous direct contact with 2 infected pigs for 18–42 h	2/32	11/16	11/16	12/16			6/16									[59]
Large white cross	O1 Lausanne 4.1 μg/dose Oil	Homologous indirect aerosol from 3 infectious pigs for 1 h	1/3			1/6				1/16			2/6		1/6	6/6		[25]
Large white and Landrace cross	C1 Oberbayern 2.9 μg/dose Oil	Homologous indirect aerosol from 3 infectious pigs for 1 h	0/3			5/5				6/6			6/6		6/6	6/6		[57]
		Homologous indirect aerosol from 3 infectious pigs for 4 h	0/3	0/3	0/3		1/3		3/3
Large white and Landrace cross	O1 Lausanne 6.1 μg/dose Oil	Homologous direct contact with 2 infectious pigs for 2 h	0/3			1/3	0/3	1/3										[7]
Large white and Landrace cross	O1 Manisa ? (18 PD50) Oil	Semi-heterologous direct contact with 2 infectious pigs for 9 h	0/6								3/16						6/8	[51]

^aNot specified

^bvaccine serotype

^cnumber protected/total number in group

^dconcentration of antigen/dose

^evaccine type.